S-adenosyl-L-methionine Treatment for Alcoholic Liver Disease: A Double-Blinded, Randomized, Placebo-Controlled Trial
Лечение алкогольной болезни печени S-аденозил-L-метионином: двойное слепое рандомизированное плацебо-контролируемое исследование
2011-11-01
SCID: 54.1/6p338yrp
Discuss with AI
S-adenosyl-L-methioninealcoholic liver diseaseaminotransferase levelsliver histopathologyrandomized placebo-controlled trial
Figures from the paper
Abstract (AI)
BACKGROUND: S-adenosyl-L-methionine (SAM) is the methyl donor for all methylation reactions and regulates the synthesis of glutathione, the main cellular antioxidant. Previous experimental studies suggested that SAM may benefit patients with established alcoholic liver diseases (ALDs). The aim of this study was to determine the efficacy of SAM in treatment for ALD in a 24-week trial. The primary endpoints were changes in serum aminotransferase levels and liver histopathology scores, and the secondary endpoints were changes in serum levels of methionine metabolites. METHODS: We randomized 37 patients with ALD to receive 1.2 g of SAM by mouth or placebo daily. Subjects were required to remain abstinent from alcohol drinking. A baseline liver biopsy was performed in 24 subjects, and a posttreatment liver biopsy was performed in 14 subjects. RESULTS: Fasting serum SAM levels were increased over timed intervals in the SAM treatment group. The entire cohort showed an overall improvement of AST, ALT, and bilirubin levels after 24 weeks of treatment, but there were no differences between the treatment groups in any clinical or biochemical parameters nor any intra- or intergroup differences or changes in liver histopathology scores for steatosis, inflammation, fibrosis, and Mallory-Denk hyaline bodies. CONCLUSIONS: Whereas abstinence improved liver function, 24 weeks of therapy with SAM was no more effective than placebo in the treatment for ALD.
Key Findings
1
A 24-week double-blind, randomized, placebo-controlled trial evaluated oral S-adenosyl-L-methionine at 1.2 g daily in 37 patients with alcoholic liver disease.
2
After 24 weeks, the overall cohort showed improved AST, ALT, and bilirubin levels, consistent with the benefit of alcohol abstinence.
3
Fasting serum S-adenosyl-L-methionine levels increased over time in the active-treatment group, confirming treatment exposure.
4
No treatment-related differences were observed in steatosis, inflammation, fibrosis, or Mallory-Denk hyaline body scores.
5
S-adenosyl-L-methionine was no more effective than placebo for clinical, biochemical, or liver histopathology outcomes.
Research Object
Patients with established alcoholic liver disease (ALD) undergoing 24-week SAM or placebo treatment while abstinent from alcohol
Research Subject
The efficacy of S-adenosyl-L-methionine (SAM) in improving liver function, serum aminotransferase and methionine-metabolite levels, and liver histopathology compared with placebo
Publication Details
Publication Date
2011-11-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest